Koch study finds promising new drug for PPMS

January 24, 2022

Multiple Sclerosis (MS) impacts over 90,000 people in Canada. About 15% of those living with MS have a primary progressive form of the disease, the least treatable variety.

Dr. Marcus Koch and his team recently completed a small phase II futility trial that examined the effectiveness of hydroxycholoroquine, a drug developed to prevent malaria, in people living with primary progressive MS. Of the 35 patients followed for 18 months, 14 were expected to experience significant worsening disability. Treatment with hydroxycholoquine reduced number that to only 8. This small trial demonstrates the promise of utilizing hydroxychloroquine to delay disability in primary progressive MS patients.

Koch MW, Kaur S, Sage K, Kim J, Levesque-Roy M, Cerchiaro G, Yong VW, Cutter GR, Metz LM. Hydroxychloroquine for Primary Progressive Multiple Sclerosis. Ann Neurol. 2021 Dec

Stories from other news outlets:


*** Due to COVID-19 pandemic, some in-person activities are temporarily suspended. However, we are offering seminars and lectures online via Zoom. Please visit our website regularly to stay updated on our current educational activities.


182A Heritage Medical Research Building
3330 Hospital Drive NW
University of Calgary
Calgary, Alberta  T2N 4N1

Automatic sign up - Temporarily Unavailable

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.